STAG2 Alleviates Anxiety Disorder via Inhibiting cGAS-STING Pathway
Corresponding Author
Fan Yang
Guangdong Mental Health Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou City, China
Correspondence: Fan Yang ([email protected])
Contribution: Conceptualization, Investigation, Writing - original draft, Writing - review & editing, Formal analysis
Search for more papers by this authorTianyi Zhai
Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou City, China
Contribution: Conceptualization, Investigation, Writing - original draft, Writing - review & editing, Formal analysis
Search for more papers by this authorXiaojie Huang
Guangdong Mental Health Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou City, China
Contribution: Methodology, Writing - review & editing
Search for more papers by this authorCorresponding Author
Fan Yang
Guangdong Mental Health Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou City, China
Correspondence: Fan Yang ([email protected])
Contribution: Conceptualization, Investigation, Writing - original draft, Writing - review & editing, Formal analysis
Search for more papers by this authorTianyi Zhai
Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou City, China
Contribution: Conceptualization, Investigation, Writing - original draft, Writing - review & editing, Formal analysis
Search for more papers by this authorXiaojie Huang
Guangdong Mental Health Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou City, China
Contribution: Methodology, Writing - review & editing
Search for more papers by this authorFan Yang and Tianyi Zhai are Co-first authors.
ABSTRACT
Anxiety is one of the most common mental disorders. We aim to find novel biomarkers to explore its potential mechanism in anxiety disorders. Differentially expressed genes (DEGs) were screened out from GSE29014 and GSE100084 datasets. Protein-protein interaction network, enrichment analysis, and principal component analysis were employed to determine hub genes. The anxiety model was constructed by restraint stress. Behavioral tests, enzyme-linked immunosorbent assay, hematoxylin-eosin, and Nissl staining were applied to evaluate the anxiety model. The potential mechanisms were investigated by corticosterone (CORT)-induced PC12 cells as an in vitro model. Proteins and mRNA expression levels were measured by western blot and real-time quantitative polymerase chain reaction. Cell counting kit, 5-Ethynyl-2’-deoxyuridine, and flow cytometry assays were employed to measure proliferation and apoptosis. PTPRC, SMC3, STAG2, FLT3, SYNE1, TERF2IP, NIPBL, ZFP451, MLLT3, and JAK1 were identified as hub genes with high prediction value for anxiety. Hippocampal neurons were damaged with decreased 5-hydroxytryptamine, γ-amino butyric acid, and neuropeptide Y, as well as increased corticotrophin releasing factor and cholecystokinin in anxiety model. PTPRC, SMC3, STAG2, SYNE1, NIPBL, and ZFP451 were downregulated in anxiety mice. STAG2 was selected as the research target. In CORT-induced PC12 cells, STAG2 overexpression promoted cell proliferation, while inhibiting apoptosis and the expression of proteins in cGAS-STING pathway. STAG2 is a potential biomarker of anxiety that exerts a neuroprotective effect on CORT-induced PC12 cells via suppressing cGAS-STING pathway.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The datasets generated and/or analysed during the current study are available by contacting the corresponding author.
Supporting Information
| Filename | Description |
|---|---|
| jbt70401-sup-0001-Supplementary_Tables.docx20.2 KB | Supplementary Table 1: Primer sequence. Supplementary Table 2: The top 15 differentially expressed genes of the GSE29014 dataset. Supplementary Table 3: The top 15 differentially expressed genes of the GSE100084 dataset. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1G. A. Brenes, “Anxiety, Depression, and Quality of Life in Primary Care Patients,” Primary Care Companion to the Journal of Clinical Psychiatry 9 (2007): 437–443.
- 2F. Alkmashri and H. Almutary, “Impact of Anxiety and Depression on the Quality of Life of Haemodialysis Patients,” Journal of Clinical Nursing (2021): 220–230.
- 3 US APAD-TFAV. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™ ( 5th ed.) (Codas, 2013), 191.
- 4A. J. Baxter, K. M. Scott, T. Vos, and H. A. Whiteford, “Global Prevalence of Anxiety Disorders: A Systematic Review and Meta-Regression,” Psychological Medicine 43 (2013): 897–910.
- 5A. Francesmonneris, H. Pincus, and M. First, Diagnostic and Statistical Manual of Mental Disorders: DSM-V (American Psychiatric Association, 2013).
- 6J. Li, Y. Zhong, Z. Ma, et al., “Emotion Reactivity-Related Brain Network Analysis in Generalized Anxiety Disorder: A Task fMRI Study,” BMC Psychiatry 20 (2020): 429.
- 7G. Griebel and A. Holmes, “50 Years of Hurdles and Hope in Anxiolytic Drug Discovery,” Nature Reviews Drug Discovery 12 (2013): 667–687.
- 8M. Sinyor, A. Schaffer, and A. Levitt, “The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review,” Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 55 (2010): 126–135.
- 9M. S. Lawrence, P. Stojanov, C. H. Mermel, et al., “Discovery and Saturation Analysis of Cancer Genes Across 21 Tumour Types,” Nature 505 (2014): 495–501.
- 10G. D. Mehta, R. Kumar, S. Srivastava, and S. K. Ghosh, “Cohesin: Functions Beyond Sister Chromatid Cohesion,” FEBS Letters 587 (2013): 2299–2312.
- 11S. V. Mullegama, S. D. Klein, M. V. Mulatinho, et al., “De Novo Loss-of-Function Variants in STAG2 Are Associated With Developmental Delay, Microcephaly, and Congenital Anomalies,” American Journal of Medical Genetics, Part A 173 (2017): 1319–1327.
- 12Z. Chu, L. Gu, Y. Hu, et al., “STAG2 Regulates Interferon Signaling in Melanoma via Enhancer Loop Reprogramming,” Nature Communications 13 (2022): 1859.
- 13Z. Shi, H. Gao, X. C. Bai, and H. Yu, “Cryo-EM Structure of the Human Cohesin-NIPBL-DNA Complex,” Science (New York, N.Y.) 368 (2020): 1454–1459.
- 14Y. Fujita, K. Masuda, M. Bando, et al., “Decreased Cohesin in the Brain Leads to Defective Synapse Development and Anxiety-Related Behavior,” Journal of Experimental Medicine 214 (2017): 1431–1452.
- 15J. Schmidt, S. Dreha-Kulaczewski, M. P. Zafeiriou, et al., “Somatic Mosaicism in STAG2-associated Cohesinopathies: Expansion of the Genotypic and Phenotypic Spectrum,” Frontiers in Cell and Developmental Biology 10 (2022): 1025332.
- 16M. Jiang, P. Chen, L. Wang, et al., “cGAS-STING, an Important Pathway in Cancer Immunotherapy,” Journal of Hematology & Oncology 13 (2020): 81.
- 17J. Sun, Y. Q. Zhou, B. Y. Xu, et al., “STING/NF-κB/IL-6-Mediated Inflammation in Microglia Contributes to Spared Nerve Injury (SNI)-Induced Pain Initiation,” Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology 17 (2022): 453–469.
- 18B. D. Paul, S. H. Snyder, and V. A. Bohr, “Signaling by CGAS–STING in Neurodegeneration, Neuroinflammation, and Aging,” Trends in Neurosciences 44 (2020): 83–96.
- 19E. Haroon, A. W. Daguanno, B. J. Woolwine, et al., “Antidepressant Treatment Resistance Is Associated With Increased Inflammatory Markers in Patients With Major Depressive Disorder,” Psychoneuroendocrinology 95 (2018): 43–49.
- 20E. F. Osimo, T. Pillinger, I. M. Rodriguez, G. M. Khandaker, C. M. Pariante, and O. D. Howes, “Inflammatory Markers in Depression: A Meta-Analysis of Mean Differences and Variability in 5166 Patients and 5083 Controls,” Brain, Behavior, and Immunity 87 (2020): 901–909.
- 21R. Strawbridge, D. Arnone, A. Danese, A. Papadopoulos, A. H. V, and A. J. Cleare, “Inflammation and Clinical Response to Treatment in Depression: A Meta-Analysis,” European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 25 (2015): 1532–1543.
- 22Y. L. Wang, Q. Q. Han, W. Q. Gong, et al., “Microglial Activation Mediates Chronic Mild Stress-Induced Depressive- and Anxiety-Like Behavior in Adult Rats,” Journal of Neuroinflammation 15 (2018): 21.
- 23A. Lt, B. Sssa, C. Lbc, et al., “Repetitive Transcranial Magnetic Stimulation Elicits Antidepressant- and Anxiolytic-Like Effect via Nuclear Factor-E2-Related Factor 2-mediated Anti-Inflammation Mechanism in Rats,” Neuroscience 429 (2020): 119–133.
- 24J. B. Belge, L. van Diermen, B. Sabbe, et al., “Inflammation, Hippocampal Volume, and Therapeutic Outcome Following Electroconvulsive Therapy in Depressive Patients: A Pilot Study,” Neuropsychobiology 79 (2020): 222–232.
- 25B. Sma, D. Mkla, D. Nfa, et al., “Repeated Stress Induces a Pro-Inflammatory State, Increases Amygdala Neuronal and Microglial Activation, and Causes Anxiety in Adult Male Rats,” Brain, Behavior, and Immunity 84 (2020): 180–199.
- 26N. Xiang, K. Shiho, T. Kohei, et al., “The Innate Immune Receptors TLR2/4 Mediate Repeated Social Defeat Stress-Induced Social Avoidance Through Prefrontal Microglial Activation,” Neuron 99 (2018): S0896627318305312.
- 27Y. Zhao, B. Liu, L. Xu, et al., “ROS-Induced mtDNA Release: The Emerging Messenger for Communication Between Neurons and Innate Immune Cells During Neurodegenerative Disorder Progression,” Antioxidants (Basel, Switzerland) 10 (2021): 1917.
- 28L. Kong, W. Li, E. Chang, et al., “mtDNA-STING Axis Mediates Microglial Polarization,” Frontiers in Immunology 13 (2022): 860977.
- 29A. C. Campos, M. V. Fogaça, D. C. Aguiar, and F. S. Guimarães, “Animal Models of Anxiety Disorders and Stress,” Braz J Psychiatry 35, no. Suppl 2 (2013): S101–S111.
- 30G. Disease, I. Incidence, L. Monasta, et al., Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (Lancet Publishing Group, 2018).
- 31H. Ask, R. Cheesman, E. S. Jami, D. F. Levey, and H. Weber, “Genetic Contributions to Anxiety Disorders: Where We Are and Where We Are Heading,” Psychological Medicine 51 (2021): 1–16.
- 32M. G. Craske, M. B. Stein, T. C. Eley, et al., “Correction: Anxiety Disorders,” Nature Reviews Disease Primers 3 (2017): 17100.
- 33Y. Xie, X. Luo, H. He, and M. Tang, “Novel Insight Into the Role of Immune Dysregulation in Amyotrophic Lateral Sclerosis Based on Bioinformatic Analysis,” Frontiers in Neuroscience 15 (2021): 657465.
- 34Y. Fujita, K. Masuda, M. Bando, et al., “Decreased Cohesin in the Brain Leads to Defective Synapse Development and Anxiety-Related Behavior,” Journal of Experimental Medicine 214 (2017): 1431–1452.
- 35J. H. Kim, J. Y. Choi, S. B. Kim, et al., “CD11chi Dendritic Cells Regulate Ly-6Chi Monocyte Differentiation to Preserve Immune-Privileged CNS in Lethal Neuroinflammation,” Scientific Reports 5 (2015): 17548.
- 36L. Amit, F. Michaela, B. Janita, et al., “Neuroinformatic Analyses of Common and Distinct Genetic Components Associated With Major Neuropsychiatric Disorders,” Frontiers in Neuroscience 8 (2014): 331.
- 37M. J. Swanson, K. N. Lewis, R. Carpenter, A. Whetzel, and N. S. Bae, “The Human RAP1 and GFAPε Proteins Increase γ-secretase Activity in a Yeast Model System,” G3 (Bethesda) 13 (2023): jkad057.
- 38A. D. Kline, M. Grados, P. Sponseller, et al., “Natural History of Aging in Cornelia De Lange Syndrome,” American Journal of Medical Genetics, Part C: Seminars in Medical Genetics 145C (2007): 248–260.
- 39G. Antonio Urrutia, H. Ramachandran, P. Cauchy, et al., “ZFP451-mediated SUMOylation of SATB2 Drives Embryonic Stem Cell Differentiation,” Genes & Development 35 (2021): 1142–1160.
- 40Y. Fujita and T. Yamashita, “Spatial Organization of Genome Architecture in Neuronal Development and Disease,” Neurochemistry International 119 (2018): 49–56.
- 41Z. Wan, M. Rasheed, Y. Li, et al., “miR-218-5p and miR-320a-5p as Biomarkers for Brain Disorders: Focus on the Major Depressive Disorder and Parkinson's Disease,” Molecular Neurobiology 60 (2023): 5642–5654.
- 42T. Li, L. Li, R. Peng, et al., “Abrocitinib Attenuates Microglia-Mediated Neuroinflammation After Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway,” Cells 11 (2022): 3588.
- 43N. Cheng, G. Li, M. Kanchwala, B. M. Evers, C. Xing, and H. Yu, “STAG2 Promotes the Myelination Transcriptional Program in Oligodendrocytes,” eLife 11 (2022): e77848.
- 44P. Kruszka, S. I. Berger, V. Casa, et al., “Cohesin Complex-Associated Holoprosencephaly,” Brain: A Journal of Neurology 142 (2019): 2631–2643.
- 45H. Bao, J. Yan, J. Huang, et al., “Activation of Endogenous Retrovirus Triggers Microglial Immuno-Inflammation and Contributes to Negative Emotional Behaviors in Mice With Chronic Stress,” Journal of Neuroinflammation 20 (2023): 37.
- 46X. Liu, W. Chen, C. Wang, et al., “Silibinin Ameliorates Depression/Anxiety-Like Behaviors of Parkinson's Disease Mouse Model and Is Associated With Attenuated STING-IRF3-IFN-β Pathway Activation and Neuroinflammation,” Physiology & Behavior 241 (2021): 113593.
- 47W. Zhang, M. Xu, F. Chen, et al., “Targeting the JAK2-STAT3 Pathway to Inhibit cGAS-STING Activation Improves Neuronal Senescence After Ischemic Stroke,” Experimental Neurology 368 (2023): 114474.
